HD-OPM Archive

Cancer and heart disease: shared prevention

Heart disease and cancer share their biggest root cause, ageing, and many of the same modifiable risk factors. This summary covers the foods and habits the group links to both, and what the evidence says about statins, aspirin, GLP-1 drugs and other heart-related drugs in cancer.

18 min read54 group posts cited50 studies discussed3 chartsEvidence through Oct 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • In the ARIC cohort of 13,253 adults, people meeting 6-7 of the American Heart Association's ideal health metrics had 51% lower cancer risk than those meeting none, and about 25% lower with smoking removed from the score.
  • The American Cancer Society estimates about 40% of US cancer cases and roughly half of cancer deaths in adults 30 and older are attributable to modifiable risk factors.
  • Processed meat is the most consistent dietary link: about 50 g a day (roughly two slices of deli ham) is tied to higher colorectal cancer risk, and one hot dog a day to a 7% higher colon cancer risk in a Nature Medicine analysis.
  • Randomized-trial meta-analyses find statins neither raise nor lower cancer (for example odds ratio 0.99 across 35 trials), so cancer is not a reason to avoid them.
  • Low-dose aspirin roughly halved colorectal cancer in people with Lynch syndrome and halved recurrence in a subgroup of colorectal cancer patients, but these are specific, closely monitored populations, not a general recommendation.
  • Low LDL in someone with cancer is usually a consequence of the tumour consuming LDL (reverse causality), not evidence that low LDL causes cancer.
In this summary
  1. Why heart disease and cancer travel together
  2. Foods and drinks: what the group links to cancer risk
  3. Nutrients and supplements: helpful, neutral or cautionary
  4. Do heart drugs affect cancer?
  5. Cancer treatment news the group has followed
  6. What this means for you
  7. Frequently asked questions
  8. The evidence behind this summary

Heart disease and cancer look like very different illnesses, but they have a great deal in common. Louis Nervegna, one of the group's admins, argues that the main shared risk factor is age, because the ageing process itself drives both conditions, so measures that slow ageing and tidy up common risk factors tend to lower the risk of both1. Population data support the overlap: the same risk factors that best predict heart disease also predict cancer, particularly lung and colorectal cancer2.

A 2024 American Cancer Society study estimated that four in ten cancer cases and about half of cancer deaths in US adults aged 30 and over are attributable to modifiable risk factors3.

On whether heart drugs affect cancer: statins do not appear to cause cancer, and randomized trials show a neutral effect. Aspirin has the strongest signal, particularly in colorectal cancer. GLP-1 drugs and SGLT2 inhibitors have generated promising but mostly observational data. This article separates randomized trials, observational cohorts and animal work.

51%lower cancer risk in ARIC for people meeting 6–7 ideal heart-health metrics versus none1
4 in 10US cancer cases in adults 30+ attributable to modifiable risk factors3
0.99odds ratio for cancer with statins across 35 randomized trials: no effect either way4
7%higher colon cancer risk with one hot dog a day5

Why heart disease and cancer travel together

Shared roots: age and lifestyle

Louis points out that cancer is not one disease but many, and that the main common denominator across them is age. In his view this is why there is unlikely to be a single "cure for cancer", and why prevention through diet, exercise and lifestyle, which evidence suggests slow the rate of ageing, remains the best course8. He also rejected the claim that heart disease risk and cancer risk are a "zero-sum game": because they share ageing as a cause, optimizing heart risk factors should lower cancer risk too1.

A book graph Louis shared with this argument: on a log scale, the incidence of cancer, heart attack, diabetes, stroke, dementia, heart failure and death all climb steeply with age after about 20, which the caption says makes the chance of a lethal disease a thousandfold higher between 20 and 70.
A book graph Louis shared with this argument: on a log scale, the incidence of cancer, heart attack, diabetes, stroke, dementia, heart failure and death all climb steeply with age after about 20, which the caption says makes the chance of a lethal disease a thousandfold higher between 20 and 70.1

What the cohort data show

The best-quantified link in the group's posts comes from the Atherosclerosis Risk in Communities (ARIC) study, published in Circulation in 2013. It followed 13,253 participants for 17-19 years, during which 2,880 cancers occurred. There was a graded, inverse association between the number of ideal cardiovascular health metrics (seven American Heart Association metrics measured at baseline) and cancer incidence. Participants who met 6-7 ideal metrics (just 2.7% of the cohort) had 51% lower cancer risk than those who met none. When smoking was removed from the score, the association weakened but remained: 5-6 ideal metrics were linked to 25% lower risk1. This is observational and cannot prove causation.

A JACC: CardioOncology study shared in the group likewise found that worse cardiovascular risk scores predicted greater cancer risk, with the strongest links for lung and colorectal cancer2.

Central illustration of the JACC: CardioOncology review: heart disease and cancer share risk factors (diet, weight, inactivity, smoking, blood pressure, lipids, ageing, genes), and across studies high cardiovascular risk scores went with more cancer while ideal AHA heart-health metrics went with less.
Central illustration of the JACC: CardioOncology review: heart disease and cancer share risk factors (diet, weight, inactivity, smoking, blood pressure, lipids, ageing, genes), and across studies high cardiovascular risk scores went with more cancer while ideal AHA heart-health metrics went with less.2

A passage from the Harvard-authored book Eat, Drink, and Be Healthy, quoted by Louis, makes a similar point: eating well, keeping weight in a healthy range, exercising and not smoking can prevent 80% of heart attacks, 90% of type 2 diabetes and 70% of colorectal cancer9.

The same habits could prevent most of three diseasesShare of cases that eating well, a healthy weight, exercise and not smoking can prevent, per the Harvard book Eat, Drink, and Be Healthy
Type 2 diabetes90%
Heart attacks80%
Colorectal cancer70%
An estimate quoted from a book, not the result of a single trial. Source: 9
Show data
Preventable (%)
Type 2 diabetes90%
Heart attacks80%
Colorectal cancer70%

Putting "rising cancer" headlines in perspective

Posts in the group push back on alarming headlines. A shared explainer stressed that many cancer rates (breast, lung, cervical, prostate and colorectal over 50, among others) are declining, and that rising diagnoses can partly reflect changed screening guidelines8. On early-onset colorectal cancer, Louis noted that the likelihood of being diagnosed before age 50 is about 0.3%, and that rates for ages 20-39 rose from 6.4 to about 6.46 per 100,000. He says the increase should not be minimized but is small in absolute terms8. In a separate post he put the "doubling" claim in numbers: 6.4 per 100,000 aged 20-39 in 2024 versus about half that before, and argued it barely changes overall cancer rates, which have fallen over four decades10.

US colorectal cancer rates per 100,000 people in 2024 by age group, shared with Louis's post: 6.4 at ages 20–39, far below the rates in older age groups (figure by Andrea Love for ImmunoLogic, using American Cancer Society, NCI and CDC data).
US colorectal cancer rates per 100,000 people in 2024 by age group, shared with Louis's post: 6.4 at ages 20–39, far below the rates in older age groups (figure by Andrea Love for ImmunoLogic, using American Cancer Society, NCI and CDC data).10

There is a counter-view in the group as well. A shared article reported that six obesity-related cancers (thyroid, breast, colorectal, kidney, endometrial and leukemia) are rising in people under 50 in over three-quarters of countries studied, with obesity-driven inflammation and hormonal changes as proposed drivers and a suggestion that screening alone does not explain the trend11. Obesity is associated with 13 different cancers12.

Processed meat

Processed meat is the clearest dietary signal. The International Agency for Research on Cancer (part of WHO) places it in Group 1, meaning there is strong evidence it can cause cancer in humans, especially colorectal cancer. A shared post stressed that Group 1 describes the certainty of the evidence, not the size of the risk, so bacon is not as dangerous as smoking even though both are in the category13.

Louis notes that "uncured" or "natural" ham is cured with celery-juice or sea-salt nitrates that behave like sodium nitrite, so the nitrosamine concern still applies14. The shared post he was commenting on cited about 50 g a day, roughly two slices of deli ham, as being linked to a significant rise in colorectal cancer14.

A 2025 Nature Medicine burden-of-proof meta-analysis, reviewing more than 60 earlier studies, found that habitual intake of even small amounts of processed meat, sugary drinks and trans fats was linked to type 2 diabetes, ischemic heart disease and colorectal cancer. One hot dog a day corresponded to an 11% higher risk of type 2 diabetes and a 7% higher risk of colon cancer5. The Harvard Nutrition Source summary, quoted by Louis, says there is strong evidence that red meat and especially processed meat raise colon cancer risk, and suggests limiting red meat to no more than twice a week and avoiding processed meats15.

Ultra-processed food and sugary drinks

Nurses' Health Study II data published in JAMA Oncology followed more than 29,000 women from 1991 to 2015. Those eating the most ultra-processed food (about 10 servings a day) were 45% more likely than those eating the least (about 3 a day) to have a conventional adenoma, the most common precancerous polyp, before age 5016. Louis also highlighted a Nature Metabolism study in which the glucose-plus-fructose combination found in sugar-sweetened beverages promoted colorectal cancer metastasis through the enzyme SORD. He adds that large prospective cohorts have repeatedly linked sugary drinks with colon cancer, so the paper may explain a mechanism17. The mechanistic study is laboratory work, not a human trial.

Fats: butter, plant oils and the seed-oil debate

The Harvard Nutrition Source review quoted in the group says total fat as a percentage of calories shows no significant association with cancer in adults, and the Women's Health Initiative Dietary Modification Trial found a low-fat diet did not change breast or colon cancer rates. It does mention that, in Nurses' Health Study II, premenopausal women eating the most animal fat had a 40-50% higher breast cancer risk, which the review suggests may be due to other factors such as hormones in red meat and high-fat dairy15. Louis notes a later Harvard study updates this picture.

That later study is the Harvard analysis of 221,054 adults in the Nurses' Health Study, Nurses' Health Study II and the Health Professionals Follow-Up Study, followed for more than 30 years and published in JAMA Internal Medicine. Louis shared it several times and described the magnitude as surprising18192021. The reported associations were:

  • Replacing 10 g a day of butter (just under a tablespoon) with plant oils: 17% lower risk of all-cause death and 17% lower risk of cancer death18.
  • Each extra 10 g a day of butter: 12% higher risk of cancer death; highest versus lowest butter intake: 15% higher all-cause mortality18.
  • Each extra 10 g a day of plant oil: 11% lower cancer death and 6% lower cardiovascular death; highest versus lowest plant-oil intake: 16% lower total mortality, with the biggest benefits from olive, canola and soybean oil18.
Butter tracked with more cancer deaths, plant oils with fewerChange in risk in 221,054 US health professionals followed for more than 30 years (Harvard cohorts, JAMA Internal Medicine)
Swap 10 g/day butter for plant oils: cancer death−17%
Swap 10 g/day butter for plant oils: all-cause death−17%
Highest vs lowest plant oil: total mortality−16%
Each extra 10 g/day plant oil: cancer death−11%
Each extra 10 g/day plant oil: cardiovascular death−6%
Highest vs lowest butter: all-cause mortality+15%
Each extra 10 g/day butter: cancer death+12%
Observational associations; the cohorts were about 84% women and 95% non-Hispanic white. Source: 18
Show data
Change in risk (%)
Swap 10 g/day butter for plant oils: cancer death−17%
Swap 10 g/day butter for plant oils: all-cause death−17%
Highest vs lowest plant oil: total mortality−16%
Each extra 10 g/day plant oil: cancer death−11%
Each extra 10 g/day plant oil: cardiovascular death−6%
Highest vs lowest butter: all-cause mortality+15%
Each extra 10 g/day butter: cancer death+12%

This is an observational cohort that was about 84% women and about 95% non-Hispanic white, a limitation noted in the quoted press release18. Louis's own comment was that the long-term evidence does not support treating butter as a health food21.

On the claim that seed oils cause colorectal cancer, Louis said dozens of human randomized trials show seed oils are not inflammatory, and shared an explainer noting the viral study behind the claim was a molecular screen of 40 tumour biopsies with no dietary component22.

Fibre, dairy and wine

Gokhan Can shared a long summary of the WHO-commissioned Reynolds 2019 meta-analysis (185 prospective studies and 58 trials). Intake of 25-29 g of fibre a day was linked to 15-30% lower all-cause mortality and 16-24% lower incidence of coronary heart disease, type 2 diabetes and colorectal cancer, with further benefit for each extra 8 g. A 2025 NHANES analysis suggested diminishing returns beyond about 30 g a day23.

On dairy, the 2020 NEJM review that Louis highlighted concluded that high dairy intake is likely to increase prostate cancer risk and possibly endometrial cancer, but to reduce colorectal cancer risk, with effects depending on what dairy is compared with24. An umbrella review of 54 meta-analyses shared by Gokhan linked cheese to a lower risk of ER-negative breast cancer (RR 0.89), but found no clear link to cancer mortality or prostate cancer25. A yogurt dose-response meta-analysis of 17 cohorts (896,871 participants) found lower all-cause and cardiovascular mortality but no significant association with cancer mortality26.

On alcohol, a Frontiers in Nutrition meta-analysis of 73 studies and over 4.3 million participants, shared by Louis in a post by Dr Brian Lawenda, found moderate wine intake (up to one drink a day for women, two for men) was not associated with higher overall cancer risk27. This is contested, and the post challenges the "all alcohol is the same" message rather than recommending drinking. A Harvard summary quoted in the group adds that higher folate intake appears to blunt the extra breast cancer risk seen with more than one drink a day28.

IGF-1 and ketogenic diets (more speculative)

Louis argues that high insulin and IGF-1 are linked to cancer and diabetes, that refined starch and sugar and excess animal protein raise IGF-1 most, and that people with Laron syndrome (very low IGF-1) have no documented cancer deaths, noting these claims come from videos and discussion rather than named papers29. Gokhan's "balanced look" at ketogenic diets lists possible anti-cancer effects but calls the research early-stage and presents a personal pro-keto view30.

Nutrients and supplements: helpful, neutral or cautionary

  • Folate. A Harvard Nutrition Source summary says higher folate intake over 15 or more years is linked to lower colon and breast cancer in observational studies. In a trial of people with prior polyps, 1,000 mcg a day of folic acid gave no protection and increased the risk of multiple or advanced polyps, so timing and dose matter28. Louis argues that methylfolate supplements raise methylfolate levels more than folic acid or food folate, and that high levels may feed existing precancerous cells. He takes 400 mcg of folic acid a day and suggests staying near the recommended intake31.
  • Magnesium. A summary of a Rhonda Patrick talk posted by Gokhan reports an association of higher magnesium intake with 24% lower pancreatic cancer risk per 100 mg32. A 240-person trial of magnesium glycinate in people with prior polyps shifted gut bacteria, a microbiome result rather than a cancer outcome33.
  • Vitamin D. The same talk summary says Mendelian randomization studies suggest low vitamin D has a causal effect on cancer mortality, and suggests a blood level of 40-60 ng/mL32. In a small randomized trial of 80 women receiving chemotherapy for breast cancer, 2,000 IU a day of vitamin D3 was associated with a pathological complete response of 43% versus 24% on placebo34.
  • Glutathione. Louis cautions that glutathione supplements mostly end up outside cells, and a Nature study showed some cancer cells can use extracellular glutathione as a cysteine source35.
  • BPC-157 and creatine. BPC-157 has not been shown to cause cancer, nor shown safe in people with active or high-risk cancer36. A UCLA mouse study suggested creatine may boost cancer-fighting immune cells, though earlier preclinical work was mixed37.
  • Blood donation. In a randomized trial of people at high risk for heart disease, blood donation did not lower heart attacks or strokes, but cancer deaths were half as frequent in donors after 6 years. Louis notes this is thought to reflect lower iron38.

Do heart drugs affect cancer?

Statins

Louis compiled meta-analyses of randomized trials showing statins are neutral for cancer4:

  • A 2023 meta-analysis of 35 randomized trials: cancer incidence odds ratio 0.99 (95% CI 0.95-1.03) and cancer mortality 0.99 (0.91-1.07).
  • A 2012 individual-data analysis of 27 trials and about 175,000 people: median 5 years of statin therapy had no effect on incidence of or mortality from any cancer.
  • A 2017 analysis of 21 trials and 65,196 participants: relative risk 0.97 (0.92-1.02).
  • A 2006 JAMA meta-analysis also found a neutral effect.
Statins neither raise nor lower cancerStatin versus placebo in meta-analyses of randomized trials compiled by Louis
interval clear of 1interval includes 1 (no clear difference)95% confidence interval
Cancer incidence (2023, 35 trials)0.99 (0.95–1.03)
Cancer mortality (2023, 35 trials)0.99 (0.91–1.07)
Cancer risk (2017, 21 trials, 65,196 people)0.97 (0.92–1.02)
The 2023 estimates are odds ratios and the 2017 estimate is a relative risk; all three confidence intervals cross 1. Source: 4
Show data
Odds ratio or relative risk (log scale)95% CI
Cancer incidence (2023, 35 trials)0.990.95–1.03
Cancer mortality (2023, 35 trials)0.990.91–1.07
Cancer risk (2017, 21 trials, 65,196 people)0.970.92–1.02

Cohort studies and registries, which can run for decades but cannot prove causation, have linked statin use to lower risks of advanced and fatal prostate cancer4. A Danish registry study found that starting statins within 3 years of early-stage breast cancer diagnosis was associated with a 10% lower risk of breast cancer death and 8% lower all-cause mortality, with a number needed to treat of 59 over 10 years39. Laboratory work adds mechanistic hypotheses: statins blocked an IL-33 inflammation pathway in mice, preventing chronic pancreatitis and pancreatic cancer development40. In a 2026 preclinical study, sildenafil trapped cholesterol in cancer cell lysosomes, and combining it with a statin gave stronger anti-metastatic effects than either alone41.

Low LDL and cancer: reverse causality

Louis explains that rapidly dividing tumour cells scavenge circulating LDL to build membranes, so LDL falls in people with cancer. That is why observational studies often link low LDL to higher cancer mortality, but "the low LDL is not causing the cancer; the cancer is causing the low LDL"42. The 2026 Science Advances study he shared found that aggressive TP53-mutant breast cancers depend on cholesterol and that blocking PI5P4K enzymes trapped cholesterol and disrupted mTOR signalling in laboratory models42.

Aspirin

Aspirin has the strongest randomized evidence among heart drugs:

  • Lynch syndrome. In John Burn's trial of 861 patients, 600 mg of aspirin daily for at least two years roughly halved colorectal cancer risk over 10 years. Early results from a second trial suggest 75-100 mg is as effective, and UK guidelines changed after the first trial6.
  • Colorectal cancer recurrence. In a Nordic trial run by Anna Martling's group, 160 mg of aspirin daily for three years after surgery cut recurrence by 55% in patients whose tumours had a PIK3 pathway mutation, found in about 40% of patients7. The BBC piece Louis shared notes Sweden now screens bowel cancer patients for these mutations and offers low-dose aspirin, that adverse effects were few in both trials, and that a larger trial in other cancers is under way6.
  • Mechanism. A 2025 Nature mouse study found platelet-derived thromboxane A2 suppresses CD8+ T cells via ARHGEF1; aspirin or COX-1 inhibition lifted this and reduced metastases, but only in animals with intact T-cell immunity43. An NEJM commentary framed aspirin as an immune-modulating agent and stated explicitly that it was not a recommendation for aspirin use44.

The BBC article notes aspirin can cause indigestion, bleeding, ulcers and rarely brain haemorrhage, and that who should take it regularly remains debated6.

GLP-1 drugs, SGLT2 inhibitors and metformin

At the 2026 ASCO meeting, more than 40 studies examined GLP-1 drugs and cancer. Observational findings included about 30% lower breast cancer in more than 100,000 women, nearly 96% versus about 90% five-year breast cancer survival, and less progression to stage IV in 10,225 patients12. A JAMA Network Open study found a 91% lower relative hazard of all-cause death in women with breast cancer and type 2 diabetes using GLP-1 drugs versus insulin or metformin; Louis stressed it was observational, the endpoint was all-cause death, and breast-cancer-specific benefit was not shown45.

Dr Brian Lawenda, in a post Louis shared, argues SGLT2 inhibitors may reduce heart disease, cancer and dementia risk, but most research is in people with diabetes and benefits in non-diabetics are inferred from mechanisms46. By contrast, metformin has failed in large trials as a cancer treatment in prostate and breast cancer, despite early promising signals47.

Cancer treatment news the group has followed

Many posts concern treatment rather than prevention and sit outside the heart focus:

  • A personalized mRNA melanoma vaccine given with Keytruda succeeded in a phase 3 trial of more than 1,100 patients, building on phase 2 five-year data showing roughly a 50% reduction in recurrence or death. It treats cancer after tumour removal rather than preventing it4849.
  • Daraxonrasib, an oral RAS inhibitor, raised one-year survival in previously treated metastatic pancreatic cancer from 18.7% to 53.3% in the 500-patient RASolute 302 trial50.
  • High-dose intravenous vitamin C with chemotherapy roughly doubled median survival from 8 to 16 months in a small phase 2 pancreatic cancer trial of 34 patients5152. Louis notes IV vitamin C has a long controversial history52.
  • The vitamin D analog paricalcitol plus chemotherapy gave a partial response in 10 of 24 patients versus 1 of 12 on placebo in a 36-patient trial, but the study was not designed to prove efficacy5354.

What this means for you

  • Treat heart and cancer prevention as one project: not smoking, healthy weight, exercise and a good diet appear in both the ARIC data and the ACS estimate13.
  • Limit processed meat, including "uncured" products514.
  • Be cautious with sugary drinks and ultra-processed foods1617.
  • Consider replacing butter with olive or other unsaturated plant oils (observational evidence)18.
  • Aim for adequate fibre; the Reynolds analysis points to roughly 25-29 g a day23.
  • Stay near recommended folate doses rather than high-dose supplements, especially with a history of polyps28.
  • A cancer diagnosis is not a reason to avoid statins on the evidence collected here, but any drug or supplement question in cancer care belongs with the treating team434.
  • Discuss aspirin with your doctor, especially if you have Lynch syndrome or a colorectal cancer history, because benefit and bleeding risk depend on the person6.

Frequently asked questions

Do statins cause cancer?

Not according to the randomized-trial meta-analyses Louis compiled: across 35 trials, cancer incidence and mortality odds ratios were both 0.994.

Does low LDL raise cancer risk?

Probably not. Louis explains the low-LDL and cancer association as reverse causality, with tumours consuming LDL42.

Should I take aspirin to prevent cancer?

The strongest evidence is in Lynch syndrome and in colorectal cancer patients with certain tumour mutations67. Benefits for the general population are not established in the posts, and bleeding is a real risk, so it is a conversation for your doctor.

Is colorectal cancer in young people exploding?

Louis argues the absolute risk is small (about 0.3% diagnosed before 50) but still worth lowering8; others point to rising obesity-related cancers under 5011.

Do GLP-1 drugs lower cancer risk?

Early observational data hint at lower breast cancer risk and better survival, but these are associations, not proof1245.

The evidence behind this summary50 studies · 9 meta-analyses · 12 trials · 10 observational

The 54 group posts cited above discuss 50 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 9Randomized trials 12Observational studies 10Reviews & guidelines 7Animal & lab studies 5Other sources 7

Strongest evidence discussed

All 50 studies and sources
Sources from the group (54)
  1. Heart disease and cancer share aging as a cause; ideal CV health cut cancer 51% in ARIC Louis Nervegna · Dec 31, 2024 · Facebook
  2. Worse CVD risk scores predict higher cancer risk, especially lung and colorectal cancers Louis Nervegna · Jul 24, 2025 · Facebook
  3. American Cancer Society: 40% of US cancers and ~half of cancer deaths are modifiable Louis Nervegna · Jul 13, 2024 · Facebook
  4. Statin RCT meta-analyses show no increase or decrease in cancer risk Louis Nervegna · Dec 31, 2024 · Facebook
  5. Nature Medicine: even small amounts of processed meat raise diabetes, heart, cancer risk Louis Nervegna · Oct 27, 2025 · Facebook
  6. Aspirin halved colorectal cancer in Lynch syndrome in a 861-patient RCT Louis Nervegna · Apr 26, 2026 · Facebook
  7. Low-dose aspirin halved colorectal cancer recurrence in patients with PIK3 mutations Louis Nervegna · Sep 21, 2025 · Facebook
  8. Cancer is a disease of aging; young-onset colorectal rise is small in absolute terms Louis Nervegna · Dec 30, 2024 · Facebook
  9. Free book 'Eat, Drink, and Be Healthy' recommended for the Mediterranean diet Louis Nervegna · Sep 27, 2024 · Facebook
  10. Young-adult colon cancer 'doubling' means 0.0032% to 0.0064% a year, not soaring cancer Louis Nervegna · Apr 23, 2025 · Facebook
  11. Obesity may explain rising cancer rates in adults under 50 Louis Nervegna · Feb 28, 2026 · Facebook
  12. GLP-1 drugs and cancer: ASCO studies suggest lower risk and progression (observational) Louis Nervegna · Jun 06, 2026 · Facebook
  13. IARC classifies processed meat as a Group 1 carcinogen, like tobacco and asbestos Louis Nervegna · Feb 18, 2026 · Facebook
  14. Even 'natural' uncured ham contains nitrates that form carcinogenic nitrosamines Louis Nervegna · Jan 09, 2026 · Facebook
  15. Harvard review: fat not clearly linked to cancer; red and processed meat raise colon risk Louis Nervegna · Dec 20, 2024 · Facebook
  16. Ultraprocessed foods linked to precancerous colorectal polyps in women under 50 Louis Nervegna · Nov 21, 2025 · Facebook
  17. Glucose plus fructose promotes colorectal cancer metastasis via SORD (Nature Metabolism) Louis Nervegna · Sep 22, 2025 · Facebook
  18. Replacing butter with plant oils linked to 17% lower mortality in 221,054 US adults Louis Nervegna · Mar 06, 2025 · Facebook
  19. Swapping 1 tbsp butter daily for plant oil linked to 17% lower cancer and all-cause death Louis Nervegna · Aug 04, 2025 · Facebook
  20. Replacing 10 g/day of butter with plant oils linked to 17% lower mortality Louis Nervegna · Oct 15, 2025 · Facebook
  21. Swapping 1 tbsp butter for plant oil linked to 17% lower cancer and all-cause death Louis Nervegna · Sep 14, 2026 · Facebook
  22. Dozens of RCTs show seed oils are not inflammatory; viral tumor study involved no diet Louis Nervegna · Dec 13, 2024 · Facebook
  23. Dietary fiber as a longevity intervention: 15-30% lower mortality at 25-29 g/day Gokhan Can · Dec 28, 2025 · Facebook
  24. NEJM 2020 dairy review: a mixed bag, best for fermented forms, weak for fractures Louis Nervegna · Jan 23, 2025 · Facebook
  25. Cheese umbrella review: modestly lower mortality, CVD, stroke and diabetes risk Gokhan Can · Aug 06, 2025 · Facebook
  26. Each daily yogurt serving linked to 14% lower CVD mortality in a 17-cohort meta-analysis Gokhan Can · Feb 16, 2025 · Facebook
  27. Meta-analysis of 4.3 million: moderate wine not linked to higher overall cancer risk Louis Nervegna · Jan 05, 2025 · Facebook
  28. Harvard Nutrition Source review of folate: a little is good, too much may be bad Louis Nervegna · Aug 08, 2024 · Facebook
  29. High insulin/IGF-1 tied to cancer, diabetes; Laron syndrome and low-IGF-1 mice live longer Louis Nervegna · May 13, 2025 · Facebook
  30. A balanced look at the ketogenic diet: anti-inflammatory potential and caveats Gokhan Can · Nov 26, 2023 · Facebook
  31. Methylfolate is not 'natural', and higher blood levels may promote cancer Louis Nervegna · Mar 11, 2026 · Facebook
  32. Rhonda Patrick on micronutrient deficiencies and exercise for healthy aging Gokhan Can · Mar 08, 2024 · Facebook
  33. Magnesium glycinate RCT (n=240) shifted colorectal-cancer-linked gut bacteria Louis Nervegna · Dec 12, 2025 · Facebook
  34. Vitamin D3 2,000 IU raised complete response to chemotherapy in breast cancer: 43% vs 24% Louis Nervegna · Oct 31, 2026 · Facebook
  35. Glutathione supplements mostly end up outside cells, where they don't belong Louis Nervegna · Jul 30, 2026 · Facebook
  36. BPC-157 is unproven as a cancer cause but not proven safe in people with cancer risk Louis Nervegna · May 14, 2026 · Facebook
  37. UCLA mouse study: creatine may boost cancer-fighting immune cells Louis Nervegna · Jul 15, 2026 · Facebook
  38. Blood donation halved cancer deaths in an RCT but did not lower heart attacks Louis Nervegna · Nov 12, 2025 · Facebook
  39. Statins after early breast cancer diagnosis linked to 10% lower breast cancer death Louis Nervegna · Nov 06, 2025 · Facebook
  40. Statins block an IL-33 inflammation pathway that may drive inflammation-linked cancers Louis Nervegna · Dec 05, 2024 · Facebook
  41. Statin plus sildenafil may block cancer metastasis in preclinical models Louis Nervegna · Jul 27, 2026 · Facebook
  42. Low LDL in cancer patients reflects reverse causality: tumours scavenge LDL Louis Nervegna · May 25, 2026 · Facebook
  43. Aspirin blocks platelet TXA2 suppression of T cells and reduces metastasis in mice Louis Nervegna · Dec 07, 2025 · Facebook
  44. Aspirin acts as an immune modulator via platelets and T cells, an NEJM analysis suggests Louis Nervegna · Jan 13, 2026 · Facebook
  45. GLP-1 use tied to 91% lower all-cause death in women with breast cancer and diabetes Louis Nervegna · May 12, 2026 · Facebook
  46. SGLT2 inhibitors may offer benefits beyond diabetes, argues Dr. Lawenda Louis Nervegna · Mar 05, 2025 · Facebook
  47. Metformin failed in large trials as a treatment for prostate and breast cancer Louis Nervegna · Dec 28, 2024 · Facebook
  48. Personalized mRNA vaccine succeeds in phase 3 melanoma trial after ~50% phase 2 benefit Louis Nervegna · Aug 20, 2026 · Facebook
  49. Personalized mRNA melanoma vaccine could extend to other cancers, with trials ongoing Louis Nervegna · Aug 20, 2026 · Facebook
  50. Daraxonrasib raised 1-year survival from 18.7% to 53.3% in pancreatic cancer (NEJM) Louis Nervegna · Jun 01, 2026 · Facebook
  51. IV vitamin C doubled survival from 8 to 16 months in 34 pancreatic cancer patients Louis Nervegna · Jan 29, 2026 · Facebook
  52. IV vitamin C plus chemotherapy doubled survival to 16 months in pancreatic cancer trial Louis Nervegna · Dec 04, 2024 · Facebook
  53. Paricalcitol plus chemotherapy raised partial response to 42% vs 9% in pancreatic cancer Louis Nervegna · May 30, 2026 · Facebook
  54. Paricalcitol plus chemo safe in 36 pancreatic cancer patients; reduced tumor fibroblasts Louis Nervegna · Jun 05, 2026 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary